Compare Enphase Energy Inc (ENPH) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enphase Energy Inc vs Tango Therapeutics Inc. — how do they compare? Enphase Energy Inc trades at $28.58 (market cap $4.23B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Enphase Energy Inc and Tango Therapeutics Inc. are close in size by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and Tango Therapeutics Inc. for 0 Days on average.
| ENPH | TNGX | |
|---|---|---|
Market Cap | $4.23B | $3.74B |
Volume | 4,755,897 | 3,438,781 |
Sector | Energy | Health |
52-Week High | $72.33 | $32.90 |
52-Week Low | $26.12 | $7.50 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $3.88B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $32.03, up 1.71% on the day, with a bearish technical signal but oversold RSI suggesting potential for a bounce. Revenue declined to $1.47B in 2025 from $2.3B in 2023, though net income margin improved to 11.68%. Recent news highlights product approvals and AI infrastructure developments, yet the stock faces pressure from high borrowing costs impacting the solar sector.
The outlook is mixed: analyst consensus targets $42.68 (33% upside) with 42% buy ratings, but earnings misses and solar industry headwinds pose risks. Investment opportunity hinges on execution amid competitive and macroeconomic challenges, with current valuation at a P/E of 31.71 reflecting growth expectations.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
